CRISPR technology's potential for gene editing has helped inspire the launch of a trio of closely watched biotech startups with their sights set on some cutting-edge approaches to new therapeutics. And now a team at Johns Hopkins has done some experiments to demonstrate its promise in engineering human stem cell therapies.
A research team says it has developed a new type of stem cell--capable of developing into any kind of tissue--that could pave the way to new cell lines that could be made more efficiently, opening up its potential in R&D.
Scientists from three Boston institutions have created CellNet, a computer algorithm to assist scientists in their efforts to engineer specialized cells.
Miltenyi Biotec said today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, related donors. The device, called the CliniMACS CD34 Reagent System, is designed to lower the risk of graft-versus-host disease (GVHD), which is a common complication of this type of transplant.
The FDA awarded orphan drug status to Lentigen's brain tumor stem cell treatment that protects healthy cells from a particularly toxic cancer drug. The orphan drug designation, an incentive for companies developing treatments for rare diseases, allows for 7 years of market exclusivity.
Melanoma stem cells are marked by a particular enzyme that could serve as a potent new target for treatment, a University of Colorado Cancer Center study concludes.
Scientists have successfully transplanted anti-HIV stem cells into mice that served as surrogates for infected patients. Bigger still, however, the process successfully expanded and safeguarded HIV-resistant immune cells, and the cells themselves kept growing even when confronted with the virus.